Roberts D, Schick J, Conway S, Biade S, Laub P B, Stevenson J P, Hamilton T C, O'Dwyer P J, Johnson S W
University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA.
Br J Cancer. 2005 Mar 28;92(6):1149-58. doi: 10.1038/sj.bjc.6602447.
Platinum-based chemotherapeutic regimens are ultimately unsuccessful due to intrinsic or acquired drug resistance. Understanding the molecular basis for platinum drug sensitivity/resistance is necessary for the development of new drugs and therapeutic regimens. In an effort to identify such determinants, we evaluated the expression of approximately 4000 genes using cDNA microarray screening in a panel of 14 unrelated human ovarian cancer cell lines derived from patients who were either untreated or treated with platinum-based chemotherapy. These data were analysed relative to the sensitivities of the cells to four platinum drugs (cis-diamminedichloroplatinum (cisplatin), carboplatin, DACH-(oxalato)platinum (II) (oxaliplatin) and cis-diamminedichloro (2-methylpyridine) platinum (II) (AMD473)) as well as the proliferation rate of the cells. Correlation analysis of the microarray data with respect to drug sensitivity and resistance revealed a significant association of Stat1 expression with decreased sensitivity to cisplatin (r=0.65) and AMD473 (r=0.76). These results were confirmed by quantitative RT-PCR and Western blot analyses. To study the functional significance of these findings, the full-length Stat1 cDNA was transfected into drug-sensitive A2780 human ovarian cancer cells. The resulting clones that exhibited increased Stat1 expression were three- to five-fold resistant to cisplatin and AMD473 as compared to the parental cells. The effect of inhibiting Jak/Stat signalling on platinum drug sensitivity was investigated using the Janus kinase inhibitor, AG490. Pretreatment of platinum-resistant cells with AG490 resulted in significant increased sensitivity to AMD473, but not to cisplatin or oxaliplatin. Overall, the results indicate that cDNA microarray analysis may be used successfully to identify determinants of drug sensitivity/resistance and future functional studies of other candidate genes from this database may lead to an increased understanding of the drug resistance phenotype.
基于铂的化疗方案最终会因内在或获得性耐药而失败。了解铂类药物敏感性/耐药性的分子基础对于新药和治疗方案的开发至关重要。为了确定这些决定因素,我们使用cDNA微阵列筛选技术,在一组来自未经治疗或接受过铂类化疗的患者的14个不相关的人卵巢癌细胞系中,评估了大约4000个基因的表达。这些数据相对于细胞对四种铂类药物(顺二氨二氯铂(顺铂)、卡铂、DACH-(草酸根)铂(II)(奥沙利铂)和顺二氨二氯(2-甲基吡啶)铂(II)(AMD473))的敏感性以及细胞的增殖率进行了分析。微阵列数据与药物敏感性和耐药性的相关性分析显示,Stat1表达与对顺铂(r=0.65)和AMD473(r=0.76)敏感性降低显著相关。这些结果通过定量RT-PCR和蛋白质印迹分析得到证实。为了研究这些发现的功能意义,将全长Stat1 cDNA转染到对药物敏感的A2780人卵巢癌细胞中。与亲本细胞相比,Stat1表达增加的所得克隆对顺铂和AMD473的耐药性提高了三到五倍。使用Janus激酶抑制剂AG490研究了抑制Jak/Stat信号传导对铂类药物敏感性的影响。用AG490预处理铂耐药细胞导致对AMD473的敏感性显著增加,但对顺铂或奥沙利铂则不然。总体而言,结果表明cDNA微阵列分析可成功用于识别药物敏感性/耐药性的决定因素,并且对该数据库中其他候选基因的未来功能研究可能会加深对耐药表型的理解。